vedolizumab
Selected indexed studies
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (N Engl J Med, 2013) [PMID:23964932]
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (N Engl J Med, 2013) [PMID:23964933]
- Long-term safety of vedolizumab for inflammatory bowel disease. (Aliment Pharmacol Ther, 2020) [PMID:32876349]
_Worker-drafted node — pending editorial review._
Connections
vedolizumab is a side effect of
Sources
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (2020) pubmed
- Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. (2022) pubmed
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) pubmed
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) pubmed
- Long-term safety of vedolizumab for inflammatory bowel disease. (2020) pubmed
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. (2016) pubmed
- Vedolizumab for induction and maintenance of remission in Crohn's disease. (2023) pubmed
- Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. (2022) pubmed
- Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. (2024) pubmed
- Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy. (2022) pubmed